Talk:Sofosbuvir

This is the talk page for discussing improvements to the Sofosbuvir article.
This is not a forum for general discussion of the article's subject.

Put new text under old text. Click here to start a new topic.
New to Wikipedia? Welcome! Learn to edit; get help.

Article policies

Find medical sources: Source guidelines · PubMed · Cochrane · DOAJ · Gale · OpenMD · ScienceDirect · Springer · Trip · Wiley · TWL

Archives: 1: 7 months

Pharmacology Mid‑importance

	This article is within the scope of WikiProject Pharmacology, a collaborative effort to improve the coverage of Pharmacology on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.PharmacologyWikipedia:WikiProject PharmacologyTemplate:WikiProject Pharmacologypharmacology
Mid	This article has been rated as Mid-importance on the project's importance scale.

Medicine Mid‑importance

	Medicine portal This article is within the scope of WikiProject Medicine, which recommends that medicine-related articles follow the Manual of Style for medicine-related articles and that biomedical information in any article use high-quality medical sources. Please visit the project page for details or ask questions at Wikipedia talk:WikiProject Medicine.MedicineWikipedia:WikiProject MedicineTemplate:WikiProject Medicinemedicine
Mid	This article has been rated as Mid-importance on the project's importance scale.

Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Sofosbuvir.

PubMed provides review articles from the past five years (limit to free review articles)
The TRIP database provides clinical publications about evidence-based medicine.
Other potential sources include: Centre for Reviews and Dissemination and CDC

Side effects

I don't think that long discussion of side effects belongs in the introduction (if anywhere). That's especially true of generalized, non-specific symptoms like tiredness, headache, and difficulty sleeping.

WP:MEDMOS "a long list of side effects is largely useless without some idea of which are common or serious."

We shouldn't just copy the FDA package insert (especially since Wikipedia isn't written for the practice of medicine). I would just mention those side effects that are common, significant and treatment-limiting. --Nbauman (talk) 00:49, 20 March 2017 (UTC)[reply]

The lead currently says "Common side effects include feeling tired, headache, nausea, and trouble sleeping.^[1] Side effects are generally more common in interferon-containing regimens.^[2]^: 7 Sofosbuvir may reactivate hepatitis B in those who have been previously infected.^[3]" How is that "long"? And common = between 1 and 10% of people experience them - these are the most common side effects.

References

^ "Sofosbuvir". The American Society of Health-System Pharmacists. Retrieved Nov 30, 2016.
^ "Sofosbuvir label" (PDF). FDA. August 2015.
^ "Direct-Acting Antivirals for Hepatitis C: Drug Safety Communication - Risk of Hepatitis B Reactivating". FDA. 4 October 2016. Retrieved 6 October 2016.

-- Jytdog (talk) 08:29, 20 March 2017 (UTC)[reply]

Side effects are definitely relevant for medications. The lead is also supposed to provide an overview. Doc James (talk · contribs · email) 10:25, 20 March 2017 (UTC)[reply]

with or without ribavirin and PEG

My friendly neighborhood hepatologist tells me that use " only recommended with some combination of ribavirin, peginterferon-alfa.. . is no longer true (the RIBA and PEG, not the combination with other DAA agents. See 2020 European Association for the Study of Liver Diseases guidelines"

Pawlotsky J-M, Negro F, Aghemo A, Berenguer M, Dalgard O, Dusheiko G, et al. EASL recommendations on treatment of hepatitis C: Final update of the series☆. Journal of Hepatology [Internet]. 2020 Nov 1 [cited 2021 Apr 26];73(5):1170–218. Available from: https://www.sciencedirect.com/science/article/pii/S0168827820305481 JuanTamad (talk) 06:42, 31 May 2021 (UTC)[reply]

Could you clarify? Do you mean that the combinations with ribavirin or peginterferon are no longer recommended? --ἀνυπόδητος (talk) 06:37, 4 June 2021 (UTC)[reply]

that’s right. The direct-acting agents can work without riba and peg, which are responsible for most side effects. That’s my understanding but check the EASL recommendation. JuanTamad (talk) 06:53, 4 June 2021 (UTC)[reply]

Thanks! I'll look into it when time allows. --ἀνυπόδητος (talk) 11:58, 7 June 2021 (UTC)[reply]

The European and US labels still say it's approved in combination with ribavirine. I's rather leave this to someone more knowledgeable about this subject. --ἀνυπόδητος (talk) 13:34, 24 June 2021 (UTC)[reply]

[AHFS2016-1] "Sofosbuvir". The American Society of Health-System Pharmacists. Retrieved Nov 30, 2016.

[USlabel2015-2] "Sofosbuvir label" (PDF). FDA. August 2015.

[FDAwarning2016-3] "Direct-Acting Antivirals for Hepatitis C: Drug Safety Communication - Risk of Hepatitis B Reactivating". FDA. 4 October 2016. Retrieved 6 October 2016.

[1]

[2]

[3]